share_log

Deep Dive Into Intra-Cellular Therapies Stock: Analyst Perspectives (12 Ratings)

Benzinga ·  Oct 4 13:04

12 analysts have shared their evaluations of Intra-Cellular Therapies (NASDAQ:ITCI) during the recent three months, expressing a mix of bullish and bearish perspectives.

The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.

BullishSomewhat BullishIndifferentSomewhat BearishBearish
Total Ratings37200
Last 30D01000
1M Ago03000
2M Ago23200
3M Ago10000

In the assessment of 12-month price targets, analysts unveil insights for Intra-Cellular Therapies, presenting an average target of $102.5, a high estimate of $130.00, and a low estimate of $74.00. This current average has increased by 3.02% from the previous average price target of $99.50.

1728061459_0.png

Exploring Analyst Ratings: An In-Depth Overview

In examining recent...

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment